Saul Faust to Male
This is a "connection" page, showing publications Saul Faust has written about Male.
Connection Strength
0.061
-
The Impact of Pediatric Outpatient Parenteral Antibiotic Therapy Implementation at a Tertiary Children's Hospital in the United Kingdom. Pediatr Infect Dis J. 2018 12; 37(12):e292-e297.
Score: 0.011
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 09 04; 398(10303):856-869.
Score: 0.003
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 04 10; 397(10282):1351-1362.
Score: 0.003
-
COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study. BMJ Open. 2021 03 17; 11(3):e044899.
Score: 0.003
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
Score: 0.003
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
Score: 0.003
-
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19; 383(21):2030-2040.
Score: 0.003
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 08 15; 396(10249):467-478.
Score: 0.003
-
Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25; 384(8):693-704.
Score: 0.003
-
Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. Pediatrics. 2018 09; 142(3).
Score: 0.003
-
Ecology and diversity in upper respiratory tract microbial population structures from a cross-sectional community swabbing study. J Med Microbiol. 2018 Aug; 67(8):1096-1108.
Score: 0.003
-
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Vaccine. 2018 04 19; 36(17):2300-2306.
Score: 0.003
-
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Sci Rep. 2018 02 21; 8(1):3390.
Score: 0.003
-
Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation. J Allergy Clin Immunol. 2018 04; 141(4):1479-1482.e6.
Score: 0.003
-
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. 2017 11 02; 2(21).
Score: 0.003
-
Pre-vaccine serotype composition within a lineage signposts its serotype replacement - a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK. Microb Genom. 2017 06 30; 3(6):e000119.
Score: 0.002
-
Corticosteroids and infliximab impair the performance of interferon-? release assays used for diagnosis of latent tuberculosis. Thorax. 2017 10; 72(10):946-949.
Score: 0.002
-
The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine. 2017 03 01; 35(9):1293-1298.
Score: 0.002
-
Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine. 2016 12 07; 34(50):6350-6357.
Score: 0.002